Login to Your Account

Neuralstem rocked on phase II miss of NSI-189 in MDD, but presses on

By Marie Powers
News Editor

Tuesday, July 25, 2017

"This is an exciting opportunity for us," Rich Daly, chairman and CEO of Neuralstem Inc., said about top-line phase II data of NSI-189 to treat major depressive disorder (MDD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription